Implication of Intra-Tumor Heterogeneity on Colorectal Cancer Response to MEK Inhibition
Intra-tumor heterogeneity (ITH) poses a major obstacle in cancer therapy. In colorectal cancer (CRC), mutations in the transforming growth factor-β/bone morphogenetic protein (TGF-β/BMP) pathway, especially in the SMAD4 gene, have been correlated with decreased overall survival and are suspected to...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Biology and Life Sciences Forum |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2673-9976/21/1/19 |
| _version_ | 1797595743808126976 |
|---|---|
| author | Christian Regenbrecht |
| author_facet | Christian Regenbrecht |
| author_sort | Christian Regenbrecht |
| collection | DOAJ |
| description | Intra-tumor heterogeneity (ITH) poses a major obstacle in cancer therapy. In colorectal cancer (CRC), mutations in the transforming growth factor-β/bone morphogenetic protein (TGF-β/BMP) pathway, especially in the SMAD4 gene, have been correlated with decreased overall survival and are suspected to modulate chemoresistance. We have previously shown that SMAD4<sup>R361H</sup> is associated with differential drug response towards EGFR, MEK and PI3K inhibitors. Here, we analyzed the mechanistic role of SMAD4<sup>R361H</sup> using oncoproteomics in CRISPR-engineered SMAD4<sup>R361H</sup> and CRC patient-derived organoids (PD3D<sup>®</sup>). Utilizing DigiWest<sup>®</sup> multiplex protein profiling analysis, we confirmed a stronger response to MEK inhibition in organoids harboring SMAD4<sup>R361H</sup> as compared to SMAD4<sup>wt</sup> PD3D. After 24 h of incubation with 0.03 µM trametinib, we observed a more pronounced decrease in proliferation markers, such as cyclin B1 and aurora kinase A in SMAD4<sup>R361H</sup> cells. Interestingly, there was no noticeable accumulation of caspases 3 and 9 in any organoid culture; however, there was a conspicuous trend in the accumulation of Bcl-xL in presence of SMAD4<sup>R361H</sup>. To understand the underlying mechanism of such a discrepancy, we analyzed the protein levels and phosphorylation status of other SMADs, as SMAD4<sup>R361H</sup> disrupts TGF-β/BMP signal transduction. Out of all SMADs, only SMAD5 showed significant changes in protein level and phosphorylation status in response to the treatment only in SMAD4<sup>wt</sup> organoids. As previously published, BMP signaling promotes cancer cell proliferation and tumor growth. It is plausible to assume that functional loss of SMAD4 and thus loss of SMAD5 signaling renders the SMAD4<sup>R361H</sup> subpopulation of cells more sensitive to MEK inhibitors. Loss of SMAD4 was previously shown to promote chemoresistance and was associated with a higher recurrence rate in colorectal cancer. The heterogenic landscape of mutated SMAD4 within the same tumor, in this light, can give rise to multi-drug resistant disease. |
| first_indexed | 2024-03-11T02:41:43Z |
| format | Article |
| id | doaj.art-59de66f8f6fa41a5ba181c3df9ba742d |
| institution | Directory Open Access Journal |
| issn | 2673-9976 |
| language | English |
| last_indexed | 2024-03-11T02:41:43Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biology and Life Sciences Forum |
| spelling | doaj.art-59de66f8f6fa41a5ba181c3df9ba742d2023-11-18T09:34:07ZengMDPI AGBiology and Life Sciences Forum2673-99762023-03-012111910.3390/blsf2023021019Implication of Intra-Tumor Heterogeneity on Colorectal Cancer Response to MEK InhibitionChristian Regenbrecht0CELLphenomics GmbH, Robert-Rössle-Str. 10, 13125 Berlin, GermanyIntra-tumor heterogeneity (ITH) poses a major obstacle in cancer therapy. In colorectal cancer (CRC), mutations in the transforming growth factor-β/bone morphogenetic protein (TGF-β/BMP) pathway, especially in the SMAD4 gene, have been correlated with decreased overall survival and are suspected to modulate chemoresistance. We have previously shown that SMAD4<sup>R361H</sup> is associated with differential drug response towards EGFR, MEK and PI3K inhibitors. Here, we analyzed the mechanistic role of SMAD4<sup>R361H</sup> using oncoproteomics in CRISPR-engineered SMAD4<sup>R361H</sup> and CRC patient-derived organoids (PD3D<sup>®</sup>). Utilizing DigiWest<sup>®</sup> multiplex protein profiling analysis, we confirmed a stronger response to MEK inhibition in organoids harboring SMAD4<sup>R361H</sup> as compared to SMAD4<sup>wt</sup> PD3D. After 24 h of incubation with 0.03 µM trametinib, we observed a more pronounced decrease in proliferation markers, such as cyclin B1 and aurora kinase A in SMAD4<sup>R361H</sup> cells. Interestingly, there was no noticeable accumulation of caspases 3 and 9 in any organoid culture; however, there was a conspicuous trend in the accumulation of Bcl-xL in presence of SMAD4<sup>R361H</sup>. To understand the underlying mechanism of such a discrepancy, we analyzed the protein levels and phosphorylation status of other SMADs, as SMAD4<sup>R361H</sup> disrupts TGF-β/BMP signal transduction. Out of all SMADs, only SMAD5 showed significant changes in protein level and phosphorylation status in response to the treatment only in SMAD4<sup>wt</sup> organoids. As previously published, BMP signaling promotes cancer cell proliferation and tumor growth. It is plausible to assume that functional loss of SMAD4 and thus loss of SMAD5 signaling renders the SMAD4<sup>R361H</sup> subpopulation of cells more sensitive to MEK inhibitors. Loss of SMAD4 was previously shown to promote chemoresistance and was associated with a higher recurrence rate in colorectal cancer. The heterogenic landscape of mutated SMAD4 within the same tumor, in this light, can give rise to multi-drug resistant disease.https://www.mdpi.com/2673-9976/21/1/19intra-tumor heterogeneitycancercellular pathology |
| spellingShingle | Christian Regenbrecht Implication of Intra-Tumor Heterogeneity on Colorectal Cancer Response to MEK Inhibition Biology and Life Sciences Forum intra-tumor heterogeneity cancer cellular pathology |
| title | Implication of Intra-Tumor Heterogeneity on Colorectal Cancer Response to MEK Inhibition |
| title_full | Implication of Intra-Tumor Heterogeneity on Colorectal Cancer Response to MEK Inhibition |
| title_fullStr | Implication of Intra-Tumor Heterogeneity on Colorectal Cancer Response to MEK Inhibition |
| title_full_unstemmed | Implication of Intra-Tumor Heterogeneity on Colorectal Cancer Response to MEK Inhibition |
| title_short | Implication of Intra-Tumor Heterogeneity on Colorectal Cancer Response to MEK Inhibition |
| title_sort | implication of intra tumor heterogeneity on colorectal cancer response to mek inhibition |
| topic | intra-tumor heterogeneity cancer cellular pathology |
| url | https://www.mdpi.com/2673-9976/21/1/19 |
| work_keys_str_mv | AT christianregenbrecht implicationofintratumorheterogeneityoncolorectalcancerresponsetomekinhibition |